Human telomerase reverse transcriptase regulation by DNA methylation, transcription factor binding and alternative splicing (Review)
- Authors:
- Brittany A. Avin
- Christopher B. Umbricht
- Martha A. Zeiger
-
Affiliations: Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA - Published online on: October 20, 2016 https://doi.org/10.3892/ijo.2016.3743
- Pages: 2199-2205
This article is mentioned in:
Abstract
Lü MH, Liao ZL, Zhao XY, Fan YH, Lin XL, Fang DC, Guo H and Yang SM: hTERT-based therapy: A universal anticancer approach (Review). Oncol Rep. 28:1945–1952. 2012.PubMed/NCBI | |
Wong MS, Chen L, Foster C, Kainthla R, Shay JW and Wright WE: Regulation of telomerase alternative splicing: A target for chemotherapy. Cell Rep. 3:1028–1035. 2013. View Article : Google Scholar : PubMed/NCBI | |
Koziel JE, Fox MJ, Steding CE, Sprouse AA and Herbert BS: Medical genetics and epigenetics of telomerase. J Cell Mol Med. 15:457–467. 2011. View Article : Google Scholar : PubMed/NCBI | |
Umbricht CB, Sherman ME, Dome J, Carey LA, Marks J, Kim N and Sukumar S: Telomerase activity in ductal carcinoma in situ and invasive breast cancer. Oncogene. 18:3407–3414. 1999. View Article : Google Scholar : PubMed/NCBI | |
Castelo-Branco P, Choufani S, Mack S, Gallagher D, Zhang C, Lipman T, Zhukova N, Walker EJ, Martin D, Merino D, et al: Methylation of the TERT promoter and risk stratification of childhood brain tumours: An integrative genomic and molecular study. Lancet Oncol. 14:534–542. 2013. View Article : Google Scholar : PubMed/NCBI | |
Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 20:603–610. 2013. View Article : Google Scholar : PubMed/NCBI | |
Kyo S, Takakura M, Fujiwara T and Inoue M: Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 99:1528–1538. 2008. View Article : Google Scholar : PubMed/NCBI | |
Adams RL: Eukaryotic DNA methyltransferases - structure and function. BioEssays. 17:139–145. 1995. View Article : Google Scholar : PubMed/NCBI | |
Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RW, Baylin SB and Schuebel KE: De novo CpG island methylation in human cancer cells. Cancer Res. 66:682–692. 2006. View Article : Google Scholar : PubMed/NCBI | |
Wan J, Oliver VF, Wang G, Zhu H, Zack DJ, Merbs SL and Qian J: Characterization of tissue-specific differential DNA methylation suggests distinct modes of positive and negative gene expression regulation. BMC Genomics. 16:492015. View Article : Google Scholar : PubMed/NCBI | |
Deaton AM and Bird A: CpG islands and the regulation of transcription. Genes Dev. 25:1010–1022. 2011. View Article : Google Scholar : PubMed/NCBI | |
Baylin SB and Jones PA: A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI | |
Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, Frommer M and Clark SJ: Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res. 57:2229–2237. 1997.PubMed/NCBI | |
Smith IM, Glazer CA, Mithani SK, Ochs MF, Sun W, Bhan S, Vostrov A, Abdullaev Z, Lobanenkov V, Gray A, et al: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One. 4:e49612009. View Article : Google Scholar : PubMed/NCBI | |
Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI | |
Tahira AC, Kubrusly MS, Faria MF, Dazzani B, Fonseca RS, Maracaja-Coutinho V, Verjovski-Almeida S, Machado MC and Reis EM: Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Mol Cancer. 10:1412011. View Article : Google Scholar : PubMed/NCBI | |
Hangauer MJ, Vaughn IW and McManus MT: Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet. 9:e10035692013. View Article : Google Scholar : PubMed/NCBI | |
Choi JH, Park SH, Park J, Park BG, Cha SJ, Kong KH, Lee KH and Park AJ: Site-specific methylation of CpG nucleotides in the hTERT promoter region can control the expression of hTERT during malignant progression of colorectal carcinoma. Biochem Biophys Res Commun. 361:615–620. 2007. View Article : Google Scholar : PubMed/NCBI | |
Zinn RL, Pruitt K, Eguchi S, Baylin SB and Herman JG: hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res. 67:194–201. 2007. View Article : Google Scholar : PubMed/NCBI | |
Guilleret I and Benhattar J: Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines. Biochem Biophys Res Commun. 325:1037–1043. 2004. View Article : Google Scholar : PubMed/NCBI | |
Pettigrew KA, Armstrong RN, Colyer HA, Zhang SD, Rea IM, Jones RE, Baird DM and Mills KI: Differential TERT promoter methylation and response to 5-aza-2′-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death. Genes Chromosomes Cancer. 51:768–780. 2012. View Article : Google Scholar : PubMed/NCBI | |
Iliopoulos D, Satra M, Drakaki A, Poultsides GA and Tsezou A: Epigenetic regulation of hTERT promoter in hepatocellular carcinomas. Int J Oncol. 34:391–399. 2009.PubMed/NCBI | |
de Wilde J, Kooter JM, Overmeer RM, Claassen-Kramer D, Meijer CJ, Snijders PJ and Steenbergen RD: hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis. BMC Cancer. 10:2712010. View Article : Google Scholar : PubMed/NCBI | |
Azouz A, Wu YL, Hillion J, Tarkanyi I, Karniguian A, Aradi J, Lanotte M, Chen GQ, Chehna M and Ségal-Bendirdjian E: Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells. Leukemia. 24:613–622. 2010. View Article : Google Scholar : PubMed/NCBI | |
Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman FT, Lobanenkov V and Benhattar J: Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res. 35:1245–1256. 2007. View Article : Google Scholar : PubMed/NCBI | |
Kumari A, Srinivasan R, Vasishta RK and Wig JD: Positive regulation of human telomerase reverse transcriptase gene expression and telomerase activity by DNA methylation in pancreatic cancer. Ann Surg Oncol. 16:1051–1059. 2009. View Article : Google Scholar : PubMed/NCBI | |
Lopatina NG, Poole JC, Saldanha SN, Hansen NJ, Key JS, Pita MA, Andrews LG and Tollefsbol TO: Control mechanisms in the regulation of telomerase reverse transcriptase expression in differentiating human teratocarcinoma cells. Biochem Biophys Res Commun. 306:650–659. 2003. View Article : Google Scholar : PubMed/NCBI | |
Zhu J, Zhao Y and Wang S: Chromatin and epigenetic regulation of the telomerase reverse transcriptase gene. Protein Cell. 1:22–32. 2010. View Article : Google Scholar | |
Guilleret I and Benhattar J: Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp Cell Res. 289:326–334. 2003. View Article : Google Scholar : PubMed/NCBI | |
Tsujioka T, Yokoi A, Itano Y, Takahashi K, Ouchida M, Okamoto S, Kondo T, Suemori S, Tohyama Y and Tohyama K: Five-aza-2′-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells. Sci Rep. 5:167092015. View Article : Google Scholar | |
Prendergast G and Ziff E: Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science. 251:186–189. 1991. View Article : Google Scholar : PubMed/NCBI | |
Sitaram RT, Degerman S, Ljungberg B, Andersson E, Oji Y, Sugiyama H, Roos G and Li A: Wilms’ tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br J Cancer. 103:1255–1262. 2010. View Article : Google Scholar : PubMed/NCBI | |
Drummond IA, Rupprecht HD, Rohwer-Nutter P, Lopez-Guisa JM, Madden SL, Rauscher FJ III and Sukhatme VP: DNA recognition by splicing variants of the Wilms’ tumor suppressor, WT1. Mol Cell Biol. 14:3800–3809. 1994. View Article : Google Scholar : PubMed/NCBI | |
Shin KH, Kang MK, Dicterow E and Park NH: Hypermethylation of the hTERT promoter inhibits the expression of telomerase activity in normal oral fibroblasts and senescent normal oral keratinocytes. Br J Cancer. 89:1473–1478. 2003. View Article : Google Scholar : PubMed/NCBI | |
Renaud S, Loukinov D, Bosman FT, Lobanenkov V and Benhattar J: CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res. 33:6850–6860. 2005. View Article : Google Scholar : PubMed/NCBI | |
Feldmann A, Ivanek R, Murr R, Gaidatzis D, Burger L and Schübeler D: Transcription factor occupancy can mediate active turnover of DNA methylation at regulatory regions. PLoS Genet. 9:e10039942013. View Article : Google Scholar : PubMed/NCBI | |
Choi JH, Min NY, Park J, Kim JH, Park SH, Ko YJ, Kang Y, Moon YJ, Rhee S, Ham SW, et al: TSA-induced DNMT1 downregulation represses hTERT expression via recruiting CTCF into demethylated core promoter region of hTERT in HCT116. Biochem Biophys Res Commun. 391:449–454. 2010. View Article : Google Scholar | |
Meeran SM, Patel SN and Tollefsbol TO: Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One. 5:e114572010. View Article : Google Scholar : PubMed/NCBI | |
Kornblihtt AR: Promoter usage and alternative splicing. Curr Opin Cell Biol. 17:262–268. 2005. View Article : Google Scholar : PubMed/NCBI | |
Nieto Moreno N, Giono LE, Cambindo Botto AE, Muñoz MJ and Kornblihtt AR: Chromatin, DNA structure and alternative splicing. FEBS Lett. 589:3370–3378. 2015. View Article : Google Scholar : PubMed/NCBI | |
Cramer P, Cáceres JF, Cazalla D, Kadener S, Muro AF, Baralle FE and Kornblihtt AR: Coupling of transcription with alternative splicing: RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer. Mol Cell. 4:251–258. 1999. View Article : Google Scholar : PubMed/NCBI | |
Schor IE, Gómez Acuña LI and Kornblihtt AR: Coupling between transcription and alternative splicing. Cancer Treat Res. 158:1–24. 2013. View Article : Google Scholar : PubMed/NCBI | |
Naftelberg S, Schor IE, Ast G and Kornblihtt AR: Regulation of alternative splicing through coupling with transcription and chromatin structure. Annu Rev Biochem. 84:165–198. 2015. View Article : Google Scholar : PubMed/NCBI | |
Davies RC, Calvio C, Bratt E, Larsson SH, Lamond AI and Hastie ND: WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev. 12:3217–3225. 1998. View Article : Google Scholar : PubMed/NCBI | |
Markus MA, Heinrich B, Raitskin O, Adams DJ, Mangs H, Goy C, Ladomery M, Sperling R, Stamm S and Morris BJ: WT1 interacts with the splicing protein RBM4 and regulates its ability to modulate alternative splicing in vivo. Exp Cell Res. 312:3379–3388. 2006. View Article : Google Scholar : PubMed/NCBI | |
Mohamed AM, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, et al: Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). Oncotarget. 7:2889–2909. 2016. | |
Katuri V, Gerber S, Qiu X, McCarty G, Goldstein SD, Hammers H, Montgomery E, Chen AR and Loeb DM: WT1 regulates angiogenesis in Ewing Sarcoma. Oncotarget. 5:2436–2449. 2014. View Article : Google Scholar : PubMed/NCBI | |
Cunningham TJ, Palumbo I, Grosso M, Slater N and Miles CG: WT1 regulates murine hematopoiesis via maintenance of VEGF isoform ratio. Blood. 122:188–192. 2013. View Article : Google Scholar : PubMed/NCBI | |
Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, et al: WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 20:768–780. 2011. View Article : Google Scholar : PubMed/NCBI | |
Radan L, Hughes CS, Teichroeb JH, Vieira Zamora FM, Jewer M, Postovit LM and Betts DH: Microenvironmental regulation of telomerase isoforms in human embryonic stem cells. Stem Cells Dev. 23:2046–2066. 2014. View Article : Google Scholar : PubMed/NCBI | |
Yatabe N, Kyo S, Maida Y, Nishi H, Nakamura M, Kanaya T, Tanaka M, Isaka K, Ogawa S and Inoue M: HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene. 23:3708–3715. 2004. View Article : Google Scholar : PubMed/NCBI | |
Nishi H, Nakada T, Kyo S, Inoue M, Shay JW and Isaka K: Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol. 24:6076–6083. 2004. View Article : Google Scholar : PubMed/NCBI | |
Anderson CJ, Hoare SF, Ashcroft M, Bilsland AE and Keith WN: Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene. 25:61–69. 2006. | |
Kechris K, Yang YH and Yeh RF: Prediction of alternatively skipped exons and splicing enhancers from exon junction arrays. BMC Genomics. 9:5512008. View Article : Google Scholar : PubMed/NCBI | |
Kornblihtt AR: CTCF: From insulators to alternative splicing regulation. Cell Res. 22:450–452. 2012. View Article : Google Scholar : PubMed/NCBI | |
Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, Oberdoerffer P, Sandberg R and Oberdoerffer S: CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature. 479:74–79. 2011. View Article : Google Scholar : PubMed/NCBI | |
Paredes SH, Melgar MF and Sethupathy P: Promoter-proximal CCCTC-factor binding is associated with an increase in the transcriptional pausing index. Bioinformatics. 29:1485–1487. 2013. View Article : Google Scholar : | |
Adelman K and Lis JT: Promoter-proximal pausing of RNA polymerase II: Emerging roles in metazoans. Nat Rev Genet. 13:720–731. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ong CT and Corces VG: CTCF: An architectural protein bridging genome topology and function. Nat Rev Genet. 15:234–246. 2014. View Article : Google Scholar : PubMed/NCBI | |
Stadhouders R, Thongjuea S, Andrieu-Soler C, Palstra RJ, Bryne JC, van den Heuvel A, Stevens M, de Boer E, Kockx C, van der Sloot A, et al: Dynamic long-range chromatin interactions control Myb proto-oncogene transcription during erythroid development. EMBO J. 31:986–999. 2012. View Article : Google Scholar : | |
Sebestyén E, Zawisza M and Eyras E: Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. Nucleic Acids Res. 43:1345–1356. 2015. View Article : Google Scholar : PubMed/NCBI | |
Ulaner GA, Hu JF, Vu TH, Giudice LC and Hoffman AR: Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int J Cancer. 91:644–649. 2001. View Article : Google Scholar : PubMed/NCBI | |
Lincz LF, Mudge LM, Scorgie FE, Sakoff JA, Hamilton CS and Seldon M: Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the β deletion variant. Neoplasia. 10:1131–1137. 2008. View Article : Google Scholar : PubMed/NCBI | |
Mavrogiannou E, Strati A, Stathopoulou A, Tsaroucha EG, Kaklamanis L and Lianidou ES: Real-time RT-PCR quantification of human telomerase reverse transcriptase splice variants in tumor cell lines and non-small cell lung cancer. Clin Chem. 53:53–61. 2007. View Article : Google Scholar | |
Listerman I, Sun J, Gazzaniga FS, Lukas JL and Blackburn EH: The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis. Cancer Res. 73:2817–2828. 2013. View Article : Google Scholar : PubMed/NCBI | |
Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA and Gerald WL: Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 19:182–186. 1998. View Article : Google Scholar : PubMed/NCBI | |
Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, et al: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 90:785–795. 1997. View Article : Google Scholar : PubMed/NCBI | |
Yi X, Shay JW and Wright WE: Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res. 29:4818–4825. 2001. View Article : Google Scholar : PubMed/NCBI | |
Kotoula V, Hytiroglou P, Pyrpasopoulou A, Saxena R, Thung SN and Papadimitriou CS: Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers. Liver. 22:57–69. 2002. View Article : Google Scholar : PubMed/NCBI | |
Ohyashiki JH, Hisatomi H, Nagao K, Honda S, Takaku T, Zhang Y, Sashida G and Ohyashiki K: Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells. Br J Cancer. 92:1942–1947. 2005. View Article : Google Scholar : PubMed/NCBI | |
Barclay JY, Morris AG and Nwokolo CU: HTERT mRNA partially regulates telomerase activity in gastric adenocarcinoma and adjacent normal gastric mucosa. Dig Dis Sci. 50:1299–1303. 2005. View Article : Google Scholar : PubMed/NCBI | |
Rha SY, Jeung HC, Park KH, Kim JJ and Chung HC: Changes of telomerase activity by alternative splicing of full-length and β variants of hTERT in breast cancer patients. Oncol Res. 18:213–220. 2009. View Article : Google Scholar | |
Liu Y, Wu BQ, Zhong HH, Tian XX and Fang WG: Quantification of alternative splicing variants of human telomerase reverse transcriptase and correlations with telomerase activity in lung cancer. PLoS One. 7:e388682012. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Meeker AK, Kowalski J, Tsai HL, Somervell H, Heaphy C, Sangenario LE, Prasad N, Westra WH, Zeiger MA, et al: Telomere length is related to alternative splice patterns of telomerase in thyroid tumors. Am J Pathol. 179:1415–1424. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wong MS, Wright WE and Shay JW: Alternative splicing regulation of telomerase: A new paradigm? Trends Genet. 30:430–438. 2014. View Article : Google Scholar : PubMed/NCBI | |
Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR and Jefferson RA: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet. 6:2011–2019. 1997. View Article : Google Scholar : PubMed/NCBI | |
Saebøe-Larssen S, Fossberg E and Gaudernack G: Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): Analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues. BMC Mol Biol. 7:262006. View Article : Google Scholar : PubMed/NCBI | |
Withers JB, Ashvetiya T and Beemon KL: Exclusion of exon 2 is a common mRNA splice variant of primate telomerase reverse transcriptases. PLoS One. 7:e480162012. View Article : Google Scholar : PubMed/NCBI | |
Khosravi-Maharlooei M, Jaberipour M, Hosseini Tashnizi A, Attar A, Amirmoezi F and Habibagahi M: Expression pattern of alternative splicing variants of human telomerase reverse Transcriptase (hTERT) in cancer cell lines was not associated with the origin of the cells. Int J Mol Cell Med. 4:109–119. 2015.PubMed/NCBI | |
Jafri MA, Ansari SA, Alqahtani MH and Shay JW: Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 8:692016. View Article : Google Scholar : PubMed/NCBI |